Activin‐A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type‐II Receptor Expression
ABSTRACT Activin‐A is elevated in pulmonary arterial hypertension (PAH) patients, and reportedly suppresses BMPR‐II. This suggests one mechanism of action for PAH drug, sotatercept, an activin‐ligand trap. However, we were unable to confirm that activin‐A reduces BMPR‐II in pulmonary endothelial cel...
Saved in:
Main Authors: | Benjamin J. Dunmore, Nobuhiro Kikuchi, Wei Li, Paul D. Upton, Nicholas W. Morrell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-04-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1002/pul2.70095 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Aspect of Bone Morphogenetic Protein Signaling and Its Relationship with Wnt Signaling in Bone
by: Kamiya, Nobuhiro
Published: (2012) -
Bioactive Ceramics as Bone Morphogenetic Proteins Carriers
by: Rabiee, Sayed Mahmood
Published: (2011) -
Bone Morphogenetic Proteins and Signaling Pathway in Inflammatory Bowel Disease
by: Maric, Ivana, et al.
Published: (2012) -
Bone Morphogenetic Protein Signaling Pathways in Heart Development and Disease
by: Harmelink, Cristina, et al.
Published: (2012) -
The Use of Mass Spectrometry in Characterization of Bone Morphogenetic Proteins from Biological Samples
by: Razdorov, Genadij, et al.
Published: (2012)